Biogen Idec - Delivering Beyond Expectations – On the Strength of Innovative Products
Promise of improved growth, increase in revenue base, and pipeline success – all have contributed to Biogen’s (BIIB) outstanding performance. Marketed products would sustain the growth due to expansion into emerging markets and label update. While a positive outcome from late-stage pipeline helps BIIB to retain its leadership in the MS space, any success from other drugs targeting niche market will be an add-on. For more detail, please read our report released on 29th July, 2011 on BIIB titled “Delivering Beyond Expectations – On the Strength of Innovative Products”.
COMPANIES MENTIONED
Biogen Idec Inc, BIIB,
Biogen Idec Inc, BIIB,
